Request An Appointment
Request An Appointment

Phone
Phone: 330-492-3345
Menu

Lymphoma

The Gabrail Cancer Center currently has many Clinical Trial opportunities . For more information and to see if you qualify call Carrie Smith R.N., Director of Research at 330-492-3345 x 208 or  via email CSmith@GabrailCancerCenter.com.

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP-196) in Subjects with Previously Untreated Mantle Cell Lymphoma.

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 and TGR-1202 alone in Patients with Previously Treated Non-Hodgkins Lymphoma

A Phase III, randomized, double-blind, controlled, multicenter study of intravenous PI3K inhibitor copanlisib in combination with standard immunochemotherapy versus standard immunochemotherapy in patients with relapsed indolent non-Hodgkin’s lymphoma (iNHL) – CHRONOS-4

AN OPEN-LABEL COMPASSIONATE USE TRAIL OF UBLITUXIMAB AND/OR UMBRALISIB (TGR-1202) IN COMBINATION WITH OTHER NOVEL AGENTS OR AS SINGLE AGENTS IN SUBJECTS CURRENTLY RECEIVING TREATMENT ON A TG THERAPEUTICS STUDY

A PHASE 1B/3 DOUBLE-BLIND, RANDOMIZED, ACTIVE-CONTROLLED, 3-STAGE, BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA

A PHASE IB/II STUDY OF APG-2575 AS A SINGLE AGENT OR IN COMBINATION WITH OTHER THERAPEUTICS AGENTS IN PATIENTS WITH RELAPSED AND/OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL) (SACRED)

An Open-label, Nonrandomized, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Belinostat in Patients with Relapsed/Refractory Solid Tumors or Hematological Malignancies Who Have Wild-Type, Heterozygous, and Homozygous UGT1A1*28 Genotypes

Return to Clinical Trials at GCC